IDEAYA Biosciences Inc (IDYA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 124.28 is considered Overvalued compared with the five-year average of -11.32. The fair price of IDEAYA Biosciences Inc (IDYA) is between 14.16 to 29.43 according to relative valuation method. Compared to the current price of 34.83 USD , IDEAYA Biosciences Inc By Overvalued By 18.33%.

Relative Value

Fair Zone

14.16-29.43

Current Price：34.83

18.33%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is IDEAYA Biosciences Inc (IDYA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

IDEAYA Biosciences Inc (IDYA) has a current Price-to-Book (P/B) ratio of 2.72. Compared to its 3-year average P/B ratio of 2.74, the current P/B ratio is approximately -0.89% higher. Relative to its 5-year average P/B ratio of 2.59, the current P/B ratio is about 4.97% higher. IDEAYA Biosciences Inc (IDYA) has a Forward Free Cash Flow (FCF) yield of approximately -3.55%. Compared to its 3-year average FCF yield of -7.97%, the current FCF yield is approximately -55.46% lower. Relative to its 5-year average FCF yield of -7.15%, the current FCF yield is about -50.33% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for IDYA competitors is 34.72, providing a benchmark for relative valuation. IDEAYA Biosciences Inc Corp (IDYA.O) exhibits a P/S ratio of 124.28, which is 257.92% above the industry average. Given its robust revenue growth of 55.37%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of IDYA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of IDYA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IDYA currently overvalued or undervalued?

What is IDEAYA Biosciences Inc (IDYA) fair value?

IDYA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of IDEAYA Biosciences Inc (IDYA) is between 14.16 to 29.43 according to relative valuation method.

How does IDYA's valuation metrics compare to the industry average?

The average P/S ratio for IDYA's competitors is 34.72, providing a benchmark for relative valuation. IDEAYA Biosciences Inc Corp (IDYA) exhibits a P/S ratio of 124.28, which is 257.92% above the industry average. Given its robust revenue growth of 55.37%, this premium appears sustainable.

What is the current P/B ratio for IDEAYA Biosciences Inc (IDYA) as of Mar 04 2026?

As of Mar 04 2026, IDEAYA Biosciences Inc (IDYA) has a P/B ratio of 2.72. This indicates that the market values IDYA at 2.72 times its book value.

What is the current FCF Yield for IDEAYA Biosciences Inc (IDYA) as of Mar 04 2026?

As of Mar 04 2026, IDEAYA Biosciences Inc (IDYA) has a FCF Yield of -3.55%. This means that for every dollar of IDEAYA Biosciences Inc's market capitalization, the company generates -3.55 cents in free cash flow.

What is the current Forward P/E ratio for IDEAYA Biosciences Inc (IDYA) as of Mar 04 2026?

As of Mar 04 2026, IDEAYA Biosciences Inc (IDYA) has a Forward P/E ratio of -9.02. This means the market is willing to pay $-9.02 for every dollar of IDEAYA Biosciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for IDEAYA Biosciences Inc (IDYA) as of Mar 04 2026?

As of Mar 04 2026, IDEAYA Biosciences Inc (IDYA) has a Forward P/S ratio of 124.28. This means the market is valuing IDYA at $124.28 for every dollar of expected revenue over the next 12 months.

IDYA Valuation